Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;41(8):653-9.
doi: 10.1016/j.ctrv.2015.05.008. Epub 2015 May 21.

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer

J Randolph Hecht  1 , Jean-Yves Douillard  2 , Lee Schwartzberg  3 , Axel Grothey  4 , Scott Kopetz  5 , Alan Rong  6 , Kelly S Oliner  6 , Roger Sidhu  6
Affiliations
Free article
Review

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer

J Randolph Hecht et al. Cancer Treat Rev. 2015 Sep.
Free article

Abstract

RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS exon 2 (codon 12/13) are an established predictor of lack of response to the anti-EGFR monoclonal antibodies cetuximab and panitumumab in patients with metastatic colorectal cancer (mCRC), and have been used routinely in clinical practice to identify patients unlikely to derive benefit from these therapies. However, a meaningful proportion of patients with mCRC have tumors bearing other mutations in RAS genes. Recent studies have demonstrated that evaluation of an extended panel of RAS mutations—including mutations in KRAS exon 2, 3, and 4 and NRAS exons 2, 3, and 4—can better define the patient population that is unlikely to benefit from anti-EGFR therapy, with concomitant improvements in outcomes in the more highly selected RAS wild-type group. This discovery has changed the practice of oncology and has the potential to spare patients from exposure to ineffective therapy. In the near future, it is important for the oncology community to validate extended RAS analysis assays and make certain that patients who are candidates for anti-EGFR therapy undergo appropriate testing and treatment.

Keywords: Biomarker; Cetuximab; EGFR; Metastatic colorectal cancer; Panitumumab; RAS mutation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms